Genelux
0 followers
GNLX
Performance
About Genelux
Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer using the CHOICE discovery platform. The company focuses on redefining immuno-oncology across multiple indications, with Olvi-Vec as its lead candidate in a Phase 3 trial for platinum-resistant/refractory ovarian cancer. Based in the United States, Genelux emphasizes a viral immunotherapy approach that aims to enhance antitumor immune responses and overcome resistance in solid tumors.
Recent News
No recent news for this company.
Recent Deals
No recent deals for this company.